Clinical trials referenced in this document:
Documents that mention this clinical trial
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
Hispanic representation in diabetes cardiovascular outcomes trials
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
Funding for this research was provided by:
Novo Nordisk A/S
Received: 20 December 2021
Accepted: 15 March 2022
First Online: 28 April 2022
: All studies were approved by Independent Ethics Committees and Institutional Review Boards at each participating center and conducted in compliance with the International Conference on Harmonisation Good Clinical Practice (GCP) guidelines and Declaration of Helsinki. All subjects provided written informed consent before any trial-related activities.
: Not applicable.
: MH reports receiving research grants from Novo Nordisk, AstraZeneca and Merck; consultancy fees for participation in advisory board meetings from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk and Roche; speaker fees from AstraZeneca, Boehringer Ingelheim, Janssen, Merck and Novo Nordisk; payment for expert testimony from Novo Nordisk; and holds one patent relating to GLP-1, and has one patent pending relating to methods for inhibiting platelet aggregation using GLP-1RAs. AC reports receiving clinical research grants from Novo Nordisk; speaker fees from Novo Nordisk, Eli Lilly, AstraZeneca and Sanofi Aventis; and remuneration for participation on data safety monitoring or advisory boards for Novo Nordisk, Eli Lilly and AstraZeneca. ADR, ASPM and SR are all employees of Novo Nordisk, and SR holds stock in the company. SB reports receiving speaker fees from Novo Nordisk; and support for attending meetings and/or travel from the American Diabetes Association and the European Association for the Study of Diabetes meetings.